Given the hypothalamus central role in energy homeostasis and its emerging vulnerability in ALS, this study aimed to determine whether hypothalamic mitochondrial dysfunction may contribute to and potentially drive disease-related metabolic disturbances, thereby representing a potential therapeutic target.